Literature DB >> 22706859

HPV testing is an efficient management choice for women with inadequate liquid-based cytology in cervical cancer screening.

Paolo Giorgi Rossi1, Francesca Carozzi, Guido Collina, Massimo Confortini, Paolo Dalla Palma, Margherita De Lillo, Annarosa Del Mistro, Bruno Ghiringhello, Anna Gillio-Tos, Patrizia Maioli, Antonella Pellegrini, Maria Luisa Schiboni, Nereo Segnan, Leandra M T Zaffina, Manuel Zorzi, Guglielmo Ronco.   

Abstract

This study compares colposcopy referrals of 2 management strategies: oncogenic human papillomavirus (HPV)-DNA testing (Hybrid Capture 2 assay, Qiagen, Germantown, MD) and repeat cytology. In the New Technology in Cervical Cancer Trial, 22,708 subjects were randomly assigned to undergo both HPV and liquid-based cytologic testing. Women aged 35 to 60 years old with unsatisfactory cytologic findings were directly referred for colposcopy if the HPV test result was positive, and were referred for repeat cytologic examination if the HPV test result was negative; women aged 25 to 35 years old were referred for repeat cytologic examination independent of HPV test results. A positive or a second unsatisfactory cytologic examination referred women for colposcopy. Five hundred sixty women had unsatisfactory cytologic findings. Colposcopy referral was not significant and slightly higher with HPV testing than repeat cytologic test (9.8% vs 6.8%, P = .11). When cytologic testing was repeated 36.8% were unavailable for follow-up and most of the colposcopies were performed in HPV-negative women. For unsatisfactory cytologic findings, HPV triage is a more logical and efficient management strategy than a repeat cytologic test.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22706859     DOI: 10.1309/AJCP6J2OEFOYTRFD

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  2 in total

1.  Female-to-male patients have high prevalence of unsatisfactory Paps compared to non-transgender females: implications for cervical cancer screening.

Authors:  Sarah M Peitzmeier; Sari L Reisner; Padmini Harigopal; Jennifer Potter
Journal:  J Gen Intern Med       Date:  2014-01-15       Impact factor: 5.128

2.  A Low-Cost HPV Immunochromatographic Assay to Detect High-Grade Cervical Intraepithelial Neoplasia.

Authors:  Vânia Sammartino Mariano; Adriana Tarlá Lorenzi; Cristovam Scapulatempo-Neto; Maíra Degiovani Stein; Julio Cesar Possati Resende; Márcio Antoniazzi; Luisa Lina Villa; José Eduardo Levi; Adhemar Longatto-Filho; José Humberto Tavares Guerreiro Fregnani
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.